127 results about "Myeloblastic leukemia" patented technology

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention provides novel application of 4-hydroxy salicylamide in the field of pharmacy. The compound is an inhibitor of ribonucleotide reductase (RR), and can achieve the aims of inhibiting replication of HBV and treating hepatitis, in particular the hepatitis B by inhibiting activity of RR enzyme to block synthesis of dNTPs (deoxynucleotide triphosphates) required by hepatitis B virus (HBV)replication, achieve the aim of preventing and treating liver cancer by inhibiting the activity of RR of liver cancer cells, including the RR activity activated by HBV to inhibit proliferation of liver cancer cells, and achieve the aim of treating various tumors by inhibiting the RR. The 4-hydroxy salicylamide can be used for preventing and treating hepatitis B, liver cancer, oropharyngeal epithelioma, colorectal cancer, ovarian cancer, non-small cell lung cancer, chronic myeloid leukemia and other tumors, and has important application prospect.

Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention belongs to the technical field of medicine, and relates to an N-substituted indole derivative, pharmaceutically acceptable salts and hydrates thereof, a pharmaceutical composition taking the derivative as an active component, and application of the derivative in preparing a myeloblastic leukemia factor-1(Mcl-1) and / or Bcl-2 protein inhibitor for treating cancer. The general structural formula of the derivative and definitions of substituents are as shown in the claims and specification.

The present invention relates to a kind of Chinese medicine for treating chronic granulocyte leukaemia and acute lymphocyte leukaemia. The Chinese medicine is prepared with 37 kinds of Chinese medicinal materials including long-noded pit viper, black-tail snake, glossy ganoderma, scorpion, bombyx batryticatus, and through crushing the materials into powder and other steps. The present invention has high curative effect ad no toxic side effect.

The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.

The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

The invention discloses a pharmaceutical composition for treating acute or chronic myeloblastic leukemia, which is characterized in that: it is made of dehydrated galactitol, kudzuvine root and pharmaceutical auxiliary materials. The composition in the invention has evident effect for treating leukemia, has an undoubted effect for treating lung cancer, multiple myeloma and nasopharyngeal carcinoma, especially has a preferable near term effect for treating chronic myeloblastic leukemia with a remission rate of 86%, has a higher effect for treating various lung cancer, and has lower poisonous and side effects.

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid / myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1 / A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and / or expression levels.

The invention relates to an application of Trichoderma pseudokoningii extracellular polysaccharides having anticancer activities. The Trichoderma pseudokoningii extracellular polysaccharides having the anticancer activities can reduce the vitality of K562 cells in vitro when they are applied to tumor growth inhibition (auxiliary) medicines, so intracellular active oxygen and free calcium ion concentrations are improved, the expression abundance of mRNA of p53 and Bax genes is improved, the expression of the Bc1-2 transcription level is reduced, the ectropion of cell membrane phosphatidylserine of the human chronic granulocyte leukemia cells K562 is induced, and the nuclear polycondensation and the fragmentation of K562 are induced to generate apoptotic bodies and apoptosis; and in-vivo administration can increase weights of tumor bearing mice and alleviate growth speeds and weights of tumors of the tumor bearing mice, thereby tumor cell killing and tumor growth inhibiting purposes are reached.

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.

Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.

The invention discloses triptolide derivative, and a preparation method and application thereof. The triptolide derivatives has the general formula as shown in Formula (I), wherein R is selected from chlorine, amine, fatty amine or aromatic amine. In the invention, triptolides, which are natural products in plants, are used as lead compounds to be modified in structure, thereby obtaining compounds capable of resisting chronic granulocytic leukemia activity in different degrees. The compounds have strong activity for inhibiting and resisting leukaemia cells, and have especially strong activity for inhibiting the chronic granulocytic leukemia cells resisting STI571. The invention lays foundation for the triptolide derivatives to develop into novel medicaments for treating the chronic granulocytic leukemia, can be used for preparing medicaments for treating the chronic granulocytic leukemia, and has good application prospects.

The invention discloses a 1, 7-meta dicarbadecaborane carboxylic acid triphenyl stannic chloride compound and a preparation method thereof. The organotin compound has high anti-cancer activity and can be used for preparing medicaments for treating chronic myeloid leukemia erythroleukemia and cervical cancers as a raw material. Compared with a platinum anti-cancer drug which is generally used at present, the organotin compound has the characteristics of high anti-cancer activity, good lipid solubility, low cost, simple preparation method and the like.

This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and / or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

The invention relates to a traditional Chinese medicine preparation for treating chronic granulocytic leukemia, comprising the following raw materials according to parts by weight: 28 to 32 parts of indigo naturalis, 14 to 16 parts of realgar, 14 to 16 parts of mastic, 0.28 to 0.32 part of musk and 14 to 16 parts of myrrh. The traditional Chinese medicine preparation has the characteristics of good curative effect, low toxicity and low price.

The invention discloses a method for establishing a PDX model of chronic myeloid leukemia, and relates to the technical field of animal models. The method specifically comprises the steps of: screening CML clinic patients in a chronic phase and an acute transformation phase, separating mononuclear cells in bone marrow, transplanting the mononuclear cells into an NSG mouse radiated by a half lethaldose, and carrying out CD34 marking before transplantation aiming at the acute transformation phase so as to screen stem / progenitor cells. A user can judge whether the model is successfully established according to the implantation ratio of human-derived cells in peripheral blood after 4-16 weeks of the transplantation. Tumor growth characteristics and cytogenetic abnormality of a series of established CML PDX mouse models are same as those of sourcing patients, so that an important preclinical study model is provided for researching pathogenesis and convulsion mechanisms of CML and screeningtargets and small molecular drugs aiming at different stages of the CML, and the method has relatively good popularization and application values.

The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and / or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

The invention discloses a Bcr / Abl tyrosine kinase inhibitor capable of treating chronic granulocytic leukemia and a preparation method thereof. The Bcr / Abl tyrosine kinase inhibitor capable of treating chronic granulocytic leukemia obtained by a large number of experimental screenings not only can effectively inhibit Bcr / Abl tyrosine kinase, and still has a good inhibitory effect to mutated Bcr / Abl tyrosine kinase, so that the Bcr / Abl tyrosine kinase inhibitor is a novel Bcr / Abl tyrosine kinase inhibitor for effectively treating chronic granulocytic leukemia.

The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein.

The invention provides a derivative which is shown in the formula (I) in the specification and is obtained by reacting an aryl carboxylic acid derivative with 2-[N-(2-methyl-5-amino phenyl)amino]-4-(3-pyridine)pyrimidine. The derivative has the anti-tumor activity and has a better suppression function to a chronic myeloblastic leukemia cell strain K562, a non-small cell lung cancer cell strain A549 and a galactophore cancer cell strain MDA-MB-45.

The invention discloses a primer for detecting IDH1 and IDH2 gene polymorphism mutation sites, a method and a kit. According to the primer, (1) an amplified IDH1 gene comprises a primer body of a 132nd amino acid sequence, and (2) an amplified IDH2 gene comprises primer bodies of 140th and 172nd amino acid sequences. A common PCR technique is adopted, the primer can be used for quickly detecting mutation situations of IDH1 and IDH2 gene polymorphism hot spots in the body of a patient suffering from acute granulocytic leukemia (AML). According to the primer, the method and the kit, the automation degree is effectively improved, complicated procedures and large detection expenses for expressed region sequencing of IDH1 and IDH2 are eliminated, the patient can be diagnosed quickly and precisely and expenses are low.

The present invention is aimed to provide oligonucleotide sequence of target activated chronic myeloid leukemia protein kinase PKR and retrovirus dual expression vector possessing the oligonucleotide sequence. The complementary sequence of 20bp SEQ1 and SEQ2 are designed according to BCR-ABL b3a2 type mRNA fusion point upper and down stream, enzyme-cutting point is also designed, a pair of nucleotides T-A is changed to C-G for preventing early stop of transcription.The recombinant retrovirus vector is transformed into K562 cell line of chronic granulocytic leukemia of blast period. The transferred gene is transcribed and hybridizes with BCR-ABL mRNA to form double-chain RNA, activates PKR targetedly, results in K562 cell apoptosis and have no effect on normal cell. The effective ingredient nucleotides sequence is prepared for clinical drug and can treat chronic granulocytic leukemia.

The invention discloses cryptotanshinone pharmaceutical composition and an application thereof in preparation of a CML (chronic myeloid leukemia) treatment drug. The cryptotanshinone pharmaceutical composition contains cryptotanshinone and a tyrosine kinase inhibitor, with the adoption of cryptotanshinone for treatment, protein expression level of Bcr-Abl genes in CML K562 and multi-drug resistantstrains K562 / ADM cells can be remarkably reduced, cell proliferation inhibition ratio of the tyrosine kinase inhibitor is increased, and apoptosis rate of CML K562 cells and K562 / ADM cells can be remarkably increased through combination of cryptotanshinone and the tyrosine kinase inhibitor. With the adoption of the cryptotanshinone pharmaceutical composition, chemosensitivity of tyrosine kinase can be improved, chemotherapy drug dosage of a patient is reduced, toxic and side effects on a human body are reduced, and a new treatment scheme is provided for clinical treatment of CML.

The invention provides the microbe polysaccharides compounds of suppressing the activity of human promyelocytic leukemia cells (HL-60) and human hepatocellular carcinoma cell (Bel-7402), and also provides its preparation method, belonging to the biological medicine technology field. The invention comprises the following steps: adopting the Penixillium oxalicum strain (CGMCC No.0907), getting the thalline and spore by liquid and solid state culture method; extracting it by boiling-water, alkali, and boiling-water and alkali respectively, finally getting the microbe polysaccharides compounds. The half lethal concentration (IC50) of microbe polysaccharides compounds in HL-60 is 0.3-2.2ª–g / mL, and when the concentration is 6.0ª–g / mL, the HL-60 doesn't grow completely; the half lethal concentration (IC50) of microbe polysaccharides compounds in Bel-7402 is 120-150ª–g / mL, and when the concentration is 300ª–g / mL, the cell doesn't grow completely.

The invention relates to a Chinese medicinal composition for treating chronic myeloid leukemia, which consists of the following components: 15 to 25 grams of rehmanniae praeparatum, 8 to 16 grams of tree peony bark, 18 to 28 grams of honey-fried extract glycyrrhiza, 18 to 32 grams of spreading hedyotis herb, 14 to 20 grams of lalang grass rhizome, 18 to 28 grams of glossy privet fruit, 14 to 28 grams of desertliving cistanche, 4 to 8 grams of cordyceps sinensis, 12 to 20 grams of Indian iphigenia bulb, 8 to 16 grams of stiff silkworm and 8 to 16 grams of eupolyphaga. The Chinese medicinal composition can carry out pertinence treatment on chronic myeloid leukemia, selectively inhibits and kills immature cells, induces apoptosis of leukemia cells, has strong pertinence and better treatment effect, promotes differentiation and maturation of leukemia cells, regulates qi and blood, strengthens the immunity, promotes recovery of the normal hematopoietic function of bone marrow, reduces reversion, prevents tolerance from being generated, reduces the toxic or side effects of chemotherapy and strengthens physical fitness.

The present invention relates to a Chinese medicine prescription for curing chronic myeloid leukemia and a preparation method thereof, pertaining to the art of Chinese medicine. The internal prescription includes 20 to 40g of radix notoginseng, 10 to 40g of field thistle, 15 to 40g of pilose deer horn, 20 to 45 of lotus powder, 20 to 50g of prepared rehmannia rhizome, 20 to 55g of donkey-hid gelatin, 20 to 60g of dangshen, 20 to 40g of milk veteh, 20 to 40g of carbonized sanguisorba root, 15 to 40g of saffron, 10 to 40g of medlar, 15 to 45g of carbonized buffalo horn, 15 to 50g of Chinese caterpillar fungus, 10 to 40g of carbonized leatherleaf millettia, 10 to 45g of carbonized black plum and 10 to 50g of carbonized hair. The external prescription includes 5 to 15g of carbonized radix notoginseng, 5 to 20g of carbonized setose thistle, 5 to 25 carbonized field thistle, 5 to 15g of carbonized human hair, 5 to 20g of carbonized petiole of windmill palm, 5 to 15g of carbonized rehmannia root and 5 to 25g of common bletilla. The oral powder made by smashing the internal materials is added with honey and made into honey pills or added with water and made into waterdewed pills. The external materials are smashed to obtain the external powder. Patients with chronic myeloid leukemia select honey pill or waterdewed pill and have one pill before three meals a day; the external powder is coated on the affected part by a tampon. Patients with chronic myeloid leukemia use the present invention both for external use and oral administration.

The invention relates to a combined medicine for treating leukemia, and application of the combined medicine. The combined medicine is prepared from 5-HT1A receptor agonist and busulfan. The combinedmedicine has a remarkable treatment effect in treatment of the leukemia, especially treatment of chronic myelogenous leukemia; compared with the singly used busulfan, the combined medicine is better in treatment effect; the combined medicine has a synergistic effect.

The invention provides a novel molecular target HES6 for treating chronic myeloid leukemia (CML), correspondingly provides a HES6-based early diagnosis kit for treating the chronic myeloid leukemia, and further provides a method for promoting K562 cell differentiation through HES6 overexpression.

The invention discloses an imatinib mesylate pill and a preparation method thereof. The imatinib is used for treating granulocytic leukemia and gastrointestinal stromal tumor. The medicine in capsules and tablets is only marketed at present, and no pill comes into the market, while for patients who have difficulties in swallowing, the pills have the obvious advantages compared with the capsules and tablets, and can improve medication compliance of patients.